Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of BOS-356 in Moderate to Severe Acne Vulgaris
NCT04163263Phase 1Completed
- Sponsor
- Boston Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of BOS-356 in acne vulgaris (6 arms), sponsored by Boston Pharmaceuticals. Primary endpoints: Number of participants with any adverse event (AE) and any serious adverse event (SAE) at Day 42, Number of participants with a mild, moderate, and severe score in local tolerability assessments (LTAs) at Day 42 and 3 more. Started Nov 2019; status: completed.
02
Drugs
BOS-356
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT04163263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163263.